TY  - JOUR
A1  - Bug, Gesine
A1  - Burchert, Andreas
A1  - Wagner, Eva-Maria
A1  - Kröger, Nicolaus
A1  - Berg, Tobias
A1  - Güller, Saskia
A1  - Metzelder, Stephan Klaus
A1  - Wolf, Andrea
A1  - Hünecke, Sabine
A1  - Bader, Peter
A1  - Schetelig, Johannes
A1  - Serve, Hubert
A1  - Ottmann, Oliver G.
T1  - Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial)
T2  - Leukemia
N2  - Maintenance therapy after allogeneic hematopoietic stem cell transplantation (HSCT) for acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) is conceptually attractive to prevent relapse, but has been hampered by the limited number of suitable anti-leukemic agents. The deacetylase inhibitor (DACi) panobinostat demonstrated moderate anti-leukemic activity in a small subset of patients with advanced AML and high-risk MDS in phase I/II trials.1, 2 It also displays immunomodulatory activity3 that may enhance leukemia-specific cytotoxicity4 and mitigate graft versus host disease (GvHD), but conversely could impair T- and NK cell function.5, 6 We conducted this open-label, multi-center phase I/II trial (NCT01451268) to assess the feasibility and preliminary efficacy of prolonged prophylactic administration of panobinostat after HSCT for AML or MDS. The study protocol was approved by an independent ethics committee and conducted in compliance with the Declaration of Helsinki. All patients provided written informed consent. ...
KW  - Acute myeloid leukaemia
KW  - Molecularly targeted therapy
KW  - Myelodysplastic syndrome
KW  - Phase I trials
KW  - Stem-cell therapies
Y1  - 2017
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/45789
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-457895
SN  - 1476-5551
SN  - 0887-6924
N1  - This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
VL  - 31
IS  - 11
SP  - 2523
EP  - 2525
PB  - Springer Nature
CY  - London
ER  -